MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) — Standard Premium Finance Holdings, Inc. (OTCQX: SPFX) (“Standard Premium”), a leading specialty finance company, today announces record-breaking second quarter earnings results highlighting the Company’s continued growth trajectory. In the three months ending June 30, 2026, Standard Premium’s net income grew 46%, with an increase of 50% to $0.12 on earnings per share (EPS), and return-on-equity of 19.25%. “Our second quarter results, including a 46% increase in net income and 50% growth in earnings per share, reflect the operating leverage we’ve built into our business model,” says William Koppelmann, CEO, Standard Premium. “Following our strongest first quarter on record, our second quarter results prove that our growth is compounding and not a one-time result. We look...

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren’s disease Pro-forma cash and investment balance of $514.5 million expected to provide runway into early 2029 BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “We continued to make meaningful progress in 2026 with telitacicept receiving its fourth and fifth commercial approvals in China for the treatment of Sjögren’s disease and IgA nephropathy and its Phase 3 TELIGAN trial in IgA nephropathy...

ST. LOUIS, Aug. 11, 2026 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2027 first quarter ended June 30, 2026. Q1 2027 Financial Key Items (all comparisons to the prior year quarter)Operating income from continuing operations of $400,249 compared to $340,174 in the prior year quarter, an increase of approximately 18% Net income was $966,511 or $0.14 per share compared to $275,624 or $0.04 per share in the prior year quarter During the quarter the Company announced it had sold to an unaffiliated purchaser substantially all of the equipment assets of its construction business, Empire Construction, Inc., and all of the real property associated with the Empire Construction businessManagement Comments Timothy M. Klusas, TMA’s Chief Executive...

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board of Directors Anticipates potential FDA approval in the first half of 2027, followed by U.S. commercial launch SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the second quarter of 2026 and provided business updates. “This...

MONTREAL, Aug. 11, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQB: TAKOF) (FSE:ABB.F) (“Volatus” or the “Company”), a Canadian-headquartered global aerospace and defence company, today announced that it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, Aug 13, 2026. Following the release of its financial results, Volatus Aerospace will host a conference call to discuss the Company’s second quarter 2026 financial results and business outlook. Earnings Conference Call Details Date: Friday, Aug 14, 2026Time: 8:30 AM Eastern Time (ET)Access: Webcast registration information below: Link: Webinar Registration – Zoom A replay of the conference call will be made available on the Company’s investor relations website at https://volatusaerospace.com following...

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expansion, expected to fund operations beyond Q2 2029, through multiple clinical milestones NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions...

Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the second quarter ended June 30, 2026 and provided business updates. “We made significant advances over the second quarter,” said Andrew Oxtoby, Chief Executive Officer of Kalaris...

Advances Phase 1 Processing Facility Construction and Gathering Infrastructure Toward Targeted First Revenue in the First Quarter of 2027 Five-Year, 100% Take-or-Pay Helium Offtake Provides Contracted Initial Revenue at a $285 per Mcf Plant-Gate Price Completes Corporate Rebrand to Big Sky Industrial Inc., with Common Stock Now Trading on Nasdaq Under Ticker Symbol “BSIN” HOUSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) — Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today reported financial and operating results for the three and six months ended June 30, 2026, while highlighting construction and development progress during the quarter at the Company’s Big Sky Carbon Hub, its flagship project in Montana. Commercial operations and first...

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients – – Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 – ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “We have successfully converted last quarter’s regulatory achievements into clinical progress in the VCN-01 program,” said Steven A. Shallcross,...

Generated $15.0 million of Gram staking revenue  Held approximately 230.5 million Gram at June 30, including approximately 229.9 million Gram deployed in staking Executed primary actions expected to remove approximately $4.0 million of inherited annual cash operating costs LAS VEGAS, Aug. 11, 2026 (GLOBE NEWSWIRE) — TON Strategy Company (“TON Strategy” or the “Company”) (Nasdaq: TONX), a digital asset treasury company dedicated to supporting the TON ecosystem, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent operational and strategic developments. Second Quarter and Recent Operational HighlightsHeld approximately 230.5 million units of Gram at June 30, 2026, including approximately 229.9 million units staked. Based on TonStat data as of August 4, 2026, the Company’s...